Walleye Capital’s Immix Biopharma IMMX Stock Holding History

Walleye Capital’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-21,926	Closed	-$67.3K	–	5782
2024 Q1	$67.3K	Buy	+21,926	New	+$84.9K	﹤0.01%	4568

Other funds holding IMMX

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Walleye Capital's IMMX Position: Q2 2024 in Review

Walleye Capital sold out of Immix Biopharma (IMMX) in Q2 2024, closing a stake of 21,926 shares — an estimated $67.3K sold.

Walleye Capital first reported a position in IMMX in Q1 2024 and held it in 1 quarter. The position peaked at $67.3K in Q1 2024. 31 funds tracked by Wall St. Rank hold IMMX as of Q2 2024.

Walleye Capital reported no remaining Immix Biopharma position as of Q2 2024 after selling out during the quarter.
Walleye Capital sold 21,926 Immix Biopharma shares in Q2 2024, an estimated $67.3K.
Walleye Capital first reported a position in Immix Biopharma in Q1 2024 and held it in 1 quarter.
Walleye Capital's Immix Biopharma position peaked at $67.3K in Q1 2024.
31 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2024.

Based on Walleye Capital's 13F filing for Q2 2024, filed 14 Aug 2024.